Clinical Efficacy and Tolerability of Monotherapy With ADX10059, a mGluR5 Negative Allosteric Modulator, for Symptom Control in Patients With Gastro-Esophageal Reflux Disease (GERD)

被引：0

|

作者：

Zerbib, Frank

Galmiche, Jean-Paul

Mion, Francois

Keywood, Charlotte

机构：

来源：

GASTROENTEROLOGY | 2010年 / 138卷 / 05期

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

W1085

引用

收藏

页码：S648 / S648

页数：1

相关论文

共 22 条

[21] Postprandial Suppression of Reflux by a Raft Forming Alginate (Gaviscon Advance) Compared to a Simple Antacid: Technical Assessment of pH-Impedance Monitoring and Clinical Feasibility Study in Gastro-Esophageal Reflux Disease (GERD) Patients
Sweis, Rami
Anggiansah, Angela
Wong, Terry
Fox, Mark R.
GASTROENTEROLOGY, 2012, 142 (05) : S92 - S92
[22] Randomized clinical trial: A double-blind, proof-of-concept, phase 2 study evaluating the efficacy and safety of vonoprazan 20 or 40 mg versus esomeprazole 40 mg in patients with symptomatic gastro-esophageal reflux disease and partial response to a healing dose of a proton-pump inhibitor
Tack, Jan
Vladimirov, Borislav
Horny, Ivo
Chong, Chui Fung
Eisner, Jessica
Czerniak, Richard
Takanami, Yohei
NEUROGASTROENTEROLOGY AND MOTILITY, 2023, 35 (01):